デフォルト表紙
市場調査レポート
商品コード
1789373

運動機能強化剤市場:薬剤の種類別、用途別、投与経路別、剤形別、性別、流通チャネル別、エンドユーザー別、地域別

Performance Enhancing Drugs Market, By Drug Type, By Application, By Route of Administration, By Dosage Form, By Gender, By Distribution Channel, By End User, By Geography


出版日
ページ情報
英文 168 Pages
納期
2~3営業日
カスタマイズ可能
運動機能強化剤市場:薬剤の種類別、用途別、投与経路別、剤形別、性別、流通チャネル別、エンドユーザー別、地域別
出版日: 2025年07月25日
発行: Coherent Market Insights
ページ情報: 英文 168 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示

  • 概要
  • 目次
概要

運動機能強化剤市場は、2025年には5億1,040万米ドルと推定され、2032年には8億4,130万米ドルに達すると予測され、2025年から2032年までの年間平均成長率(CAGR)は7.4%で成長すると予測されています。

分析範囲 分析詳細
基準年 2024年 市場規模 (2025年) 5億1,040万米ドル
実績データ 2020~2024年 予測期間 2025~2032年
予測期間のCAGR (2025~2032年) 7.40% 予測金額 (2032年) 8億4,130万米ドル

世界の運動機能強化剤市場は、身体能力、認知機能、そして様々な用途における人間の総合的なパフォーマンスを向上させるために設計された医薬品物質の複雑なエコシステムを包含しています。運動機能強化剤(PED)には、同化ステロイド、興奮剤、ペプチドホルモン、β2アゴニスト、その他の合成化合物が含まれ、治療、運動能力強化、娯楽目的で利用されています。この市場は、世界中の政府機関、アンチ・ドーピング機関、医療組織による厳しい監視のもと、高度に規制された環境下で運営されています。

医薬品セグメントには、筋肉減少性疾患、ホルモン欠乏症、呼吸器疾患、および特定の身体機能のパフォーマンス向上を必要とするその他の医学的障害を治療するための合法的な治療用途が含まれます。一方、スポーツ・フィットネス分野は、規制上の制約や倫理的な懸念があるもの、大きな市場需要を牽引し続けています。この市場の複雑さは、規制の枠組み、パフォーマンス向上に対する文化的態度、施行レベルの違いによる地域差によって、さらに増幅されています。科学的研究が進み、新しい合成化合物が出現するにつれて、市場は進化を続け、合法的な医療用途の機会と、誤用や規制遵守に関する課題の両方を提示しています。

市場力学

運動機能強化剤の世界市場は、加齢に伴う筋力低下障害の有病率の上昇、ホルモン補充療法に対する需要の増加、フィットネスやボディービルに対する意識の高まり、慢性疾患の治療における用途の拡大など、いくつかの重要な要因によって牽引されています。世界人口の高齢化は、テストステロン補充療法と成長ホルモン治療に対する大きな需要を生み出し、一方、拡大するフィットネス産業は、身体能力強化物質に対する合法・非合法両方の需要を煽り続けています。さらに、製薬研究の進歩により、特定の病状を対象とした、より洗練されたPEDが開発され、治療用途の市場成長が促進されています。

しかし、厳しい規制の枠組み、不正使用に対する厳しい法的罰則、健康リスクや副作用に対する意識の高まり、世界中のスポーツ団体による集中的なアンチ・ドーピングの取り組みなど、市場は大きな抑制要因に直面しています。世界アンチ・ドーピング機構、米国食品医薬品局、欧州医薬品庁などの規制機関は、PEDの製造、流通、使用を厳しく管理しており、市場拡大の障壁となっています。知名度の高いドーピング・スキャンダルをめぐる悪評も、消費者の受容性を低下させ、規制当局の監視を強めることで市場抑制要因となっています。こうした課題にもかかわらず、合法的な医療への応用、副作用を低減したより安全な代替品の開発、医療インフラが成長しつつある新興国市場への進出、神経変性疾患、がん性悪液質、加齢に伴う衰弱に対する治療応用の研究増加などを通じて、市場には大きな機会がもたらされています。また、ホルモン補充療法が受け入れられつつあることや、個別化医療へのアプローチの可能性も、市場参入企業に大きな成長機会をもたらしています。

当レポートの主な特徴

  • 当レポートは、世界の運動機能強化剤市場を詳細に分析し、2024年を基準年とした予測期間(2025~2032年)の市場規模・CAGRを掲載しています。
  • また、各セグメントの潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
  • また、市場の促進要因・抑制要因や機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 世界の運動機能強化剤市場における主要企業プロファイルを、企業概要、製品ポートフォリオ、主要なハイライト、財務実績、戦略などの以下のパラメータに基づいて掲載しています。
  • 当レポートの洞察を用いて、マーケティング担当者や企業の経営陣が、将来の製品発売・提携・市場拡大・マーケティング戦術に関する、十分な情報に基づいた意思決定を下すことができます。
  • 「世界の運動機能強化剤市場」レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者に対応しています。
  • 利害関係者は、世界の運動機能強化剤市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 分析目的と前提条件

  • 分析目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学・規制・動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 企業合併・買収 (M&A) のシナリオ
  • 業界動向

第4章 世界の運動機能強化剤市場:薬剤の種類別(2020~2032年)

  • アナボリックステロイド(例:テストステロン、ナンドロロン)
  • 覚醒剤(例:アンフェタミン、カフェイン、エフェドリン)
  • エリスロポエチン(EPO)と血液増強剤
  • ヒト成長ホルモン(HGH)とペプチド
  • 選択的アンドロゲン受容体モジュレーター(SARM)
  • ベータ遮断薬
  • 利尿剤
  • 向知性薬(認知機能向上薬)
  • その他(例:インスリン様成長因子)

第5章 世界の運動機能強化剤市場:用途別(2020~2032年)

  • 運動機能
  • 認知能力の向上(学生、専門家)
  • ボディビルディング・筋肉強化
  • 軍事・防衛
  • レクリエーション利用
  • アンチエイジング・ウェルネス
  • 減量・体重管理
  • その他(傷害回復・リハビリテーション)

第6章 世界の運動機能強化剤市場:投与経路別(2020~2032年)

  • 経口
  • 非経口
  • 局所
  • その他(経皮)

第7章 世界の運動機能強化剤市場:剤形別(2020~2032年)

  • 錠剤/サプリメント
  • 注射
  • パッチ
  • 経口液
  • その他(外用クリーム)

第8章 世界の運動機能強化剤市場:性別(2020~2032年)

  • 男性
  • 女性

第9章 世界の運動機能強化剤市場:流通チャネル別(2020~2032年)

  • オンライン薬局
  • 小売薬局
  • ジム・スポーツクラブ
  • 病院・診療所

第10章 世界の運動機能強化剤市場:エンドユーザー別(2020~2032年)

  • プロアスリート
  • ボディビルダーとフィットネス愛好家
  • 学生と社会人
  • 軍人
  • その他(レクリエーションユーザー)

第11章 世界の運動機能強化剤市場:地域別(2020~2032年)

  • 北米
      • 米国
      • カナダ
  • ラテンアメリカ
      • ブラジル
      • アルゼンチン
      • メキシコ
      • その他ラテンアメリカ
  • 欧州
      • ドイツ
      • 英国
      • スペイン
      • フランス
      • イタリア
      • ロシア
      • その他欧州
  • アジア太平洋
      • 中国
      • インド
      • 日本
      • オーストラリア
      • 韓国
      • ASEAN
      • その他アジア太平洋
  • 中東
      • GCC諸国
      • イスラエル
      • その他中東
  • アフリカ
      • 南アフリカ
      • 北アフリカ
      • 中央アフリカ

第12章 競合情勢

  • Pfizer Inc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Bayer AG
  • Merck and Co Inc
  • Sanofi SA
  • Eli Lilly and Company
  • AbbVie Inc
  • Roche Holding AG
  • Endo International PLC
  • Cipla Ltd
  • Lupin Ltd

第13章 アナリストの提言

  • 「運命の輪」
  • アナリストの見解
  • Coherent Opportunity Map (COM)

第14章 参考文献と調査手法

  • 参考文献
  • 分析手法
  • Coherent Market Insightsについて
目次
Product Code: CMI8315

Performance Enhancing Drugs Market is estimated to be valued at USD 510.4 Mn in 2025 and is expected to reach USD 841.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 510.4 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.40% 2032 Value Projection: USD 841.3 Mn

The global performance enhancing drugs market encompasses a complex ecosystem of pharmaceutical substances designed to improve physical capabilities, cognitive function, and overall human performance across various applications. Performance enhancing drugs (PEDs) include anabolic steroids, stimulants, peptide hormones, beta-2 agonists, and other synthetic compounds that are utilized in medical treatments, athletic performance enhancement, and recreational purposes. This market operates within a highly regulated environment, with strict oversight from governmental bodies, anti-doping agencies, and healthcare organizations worldwide.

The pharmaceutical segment includes legitimate therapeutic applications for treating muscle wasting diseases, hormone deficiencies, respiratory conditions, and other medical disorders requiring performance enhancement of specific bodily functions. Meanwhile, the sports and fitness segment, though controversial, continues to drive significant market demand despite regulatory restrictions and ethical concerns. The market's complexity is further amplified by regional variations in regulatory frameworks, cultural attitudes toward performance enhancement, and varying levels of enforcement. As scientific research advances and new synthetic compounds emerge, the market continues to evolve, presenting both opportunities for legitimate medical applications and challenges related to misuse and regulatory compliance.

Market Dynamics

The global performance enhancing drugs market is driven by several key factors, including the rising prevalence of age-related muscle wasting disorders, increasing demand for hormone replacement therapies, growing awareness about fitness and bodybuilding, and expanding applications in medical treatments for chronic diseases. The aging global population has created substantial demand for testosterone replacement therapy and growth hormone treatments, while the expanding fitness industry continues to fuel both legitimate and illicit demand for performance enhancing substances. Additionally, advancements in pharmaceutical research have led to the development of more sophisticated and targeted PEDs for specific medical conditions, driving market growth in therapeutic applications.

However, the market faces significant restraints including stringent regulatory frameworks, severe legal penalties for unauthorized use, growing awareness about health risks and side effects, and intensive anti-doping efforts by sports organizations worldwide. Regulatory bodies such as World Anti-Doping Agency, U.S Food and Drug Administration, European Medicines Agency maintain strict control over PED manufacturing, distribution, and usage, creating barriers for market expansion. The negative publicity surrounding high-profile doping scandals has also contributed to market restraints by reducing consumer acceptance and increasing regulatory scrutiny. Despite these challenges, the market presents substantial opportunities through legitimate medical applications, development of safer alternatives with reduced side effects, expansion into emerging markets with growing healthcare infrastructure, and increasing research into therapeutic applications for neurodegenerative diseases, cancer cachexia, and age-related decline. The growing acceptance of hormone replacement therapy and the potential for personalized medicine approaches also present significant growth opportunities for market participants.

Key features of the study

  • This report provides an in-depth analysis of the global performance enhancing drugs market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global performance enhancing drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals PLC, Bayer AG, Merck and Co Inc, Sanofi SA, Eli Lilly and Company, AbbVie Inc, Roche Holding AG, Endo International PLC, Cipla Ltd, and Lupin Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global performance enhancing drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global performance enhancing drugs market

Market Segmentation

  • Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
    • Anabolic Steroids (e.g., Testosterone, Nandrolone)
    • Stimulants (e.g., Amphetamines, Caffeine, Ephedrine)
    • Erythropoietin (EPO) and Blood Boosters
    • Human Growth Hormone (HGH) and Peptides
    • Selective Androgen Receptor Modulators (SARMs)
    • Beta-Blockers
    • Diuretics
    • Nootropics (Cognitive Enhancers)
    • Others (e.g. Insulin-like Growth Factor)
  • Application Insights (Revenue, USD Mn, 2020 - 2032)
    • Athletic Performance
    • Cognitive Enhancement (Students, Professionals)
    • Bodybuilding and Muscle Enhancement
    • Military and Defense
    • Recreational Use
    • Anti-Aging and Wellness
    • Weight Loss and Management
    • Others (Injury Recovery and Rehabilitation)
  • Route Of Administration Insights (Revenue, USD Mn, 2020 - 2032)
    • Oral
    • Parenteral
    • Topical
    • Others (Transdermal)
  • Dosage Form Insights (Revenue, USD Mn, 2020 - 2032)
    • Pills/supplements
    • Injections
    • Patches
    • Oral Liquids
    • Others (Topical Creams)
  • Gender Insights (Revenue, USD Mn, 2020 - 2032)
    • Male
    • Female
  • Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
    • Online Pharmacies
    • Retail Pharmacies
    • Gyms and Sports Clubs
    • Hospitals and Clinics
  • End User Insights (Revenue, USD Mn, 2020 - 2032)
    • Professional Athletes
    • Bodybuilders and Fitness Enthusiasts
    • Students and Working Professionals
    • Military Personnel
    • Others (Recretional Users)
  • Regional Insights (Revenue, USD Mn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd
    • Hikma Pharmaceuticals PLC
    • Bayer AG
    • Merck and Co Inc
    • Sanofi SA
    • Eli Lilly and Company
    • AbbVie Inc
    • Roche Holding AG
    • Endo International PLC
    • Cipla Ltd
    • Lupin Ltd

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Performance Enhancing Drugs Market, By Drug Type
    • Global Performance Enhancing Drugs Market, By Application
    • Global Performance Enhancing Drugs Market, By Route of Administration
    • Global Performance Enhancing Drugs Market, By Dosage Form
    • Global Performance Enhancing Drugs Market, By Gender
    • Global Performance Enhancing Drugs Market, By Distribution Channel
    • Global Performance Enhancing Drugs Market, By End User
    • Global Performance Enhancing Drugs Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Performance Enhancing Drugs Market, By Drug Type, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Anabolic Steroids (e.g., Testosterone, Nandrolone)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Stimulants (e.g., Amphetamines, Caffeine, Ephedrine)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Erythropoietin (EPO) and Blood Boosters
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Human Growth Hormone (HGH) and Peptides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Selective Androgen Receptor Modulators (SARMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Beta-Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Diuretics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Nootropics (Cognitive Enhancers)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others (e.g. Insulin-like Growth Factor)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Performance Enhancing Drugs Market, By Application, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Athletic Performance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Cognitive Enhancement (Students, Professionals)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Bodybuilding and Muscle Enhancement
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Military and Defense
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Recreational Use
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Anti-Aging and Wellness
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Weight Loss and Management
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others (Injury Recovery and Rehabilitation)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Performance Enhancing Drugs Market, By Route of Administration, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others (Transdermal)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Performance Enhancing Drugs Market, By Dosage Form, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pills/supplements
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Injections
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Patches
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Oral Liquids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others (Topical Creams)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Performance Enhancing Drugs Market, By Gender, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Performance Enhancing Drugs Market, By Distribution Channel, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Gyms and Sports Clubs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Performance Enhancing Drugs Market, By End User, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Professional Athletes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Bodybuilders and Fitness Enthusiasts
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Students and Working Professionals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Military Personnel
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Others (Recreational Users)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

11. Global Performance Enhancing Drugs Market, By Region, 2020 - 2032, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Pfizer Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mylan NV
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck and Co Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche Holding AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Endo International PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Lupin Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us